Buti S - Search Results

1

Combination therapy in kidney cancer: the next revolution?

Buti S, Bersanelli M. Buti S, et al. Lancet Oncol. 2015 Nov;16(15):1441-1442. doi: 10.1016/S1470-2045(15)00325-3. Epub 2015 Oct 22. Lancet Oncol. 2015. PMID: 26482275 No abstract available.

2

Chronically administered immunotherapy with low-dose IL-2 and IFN-alpha in metastatic renal cell carcinoma: a feasible option for patients with a good prognostic profile.

Vaglio A, Alberici F, Maggiore U, Buti S, Potenzoni D, Passalacqua R, Buzio C. Vaglio A, et al. Among authors: buti s. Oncology. 2009;76(1):69-76. doi: 10.1159/000178810. Epub 2008 Dec 1. Oncology. 2009. PMID: 19047813

3

Renal cell cancer: state of the art in adjuvant therapy.

Buti S, Rovere RK. Buti S, et al. Recent Pat Anticancer Drug Discov. 2010 Nov;5(3):242-50. doi: 10.2174/157489210791760544. Recent Pat Anticancer Drug Discov. 2010. PMID: 20594182 Review.

4

Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial.

Ardizzoni A, Tiseo M, Boni L, Vincent AD, Passalacqua R, Buti S, Amoroso D, Camerini A, Labianca R, Genestreti G, Boni C, Ciuffreda L, Di Costanzo F, de Marinis F, Crinò L, Santo A, Pazzola A, Barbieri F, Zilembo N, Colantonio I, Tibaldi C, Mattioli R, Cafferata MA, Camisa R, Smit EF. Ardizzoni A, et al. Among authors: buti s. J Clin Oncol. 2012 Dec 20;30(36):4501-7. doi: 10.1200/JCO.2012.43.6758. Epub 2012 Oct 29. J Clin Oncol. 2012. PMID: 23109689 Clinical Trial.

5

Chemotherapy in metastatic renal cell carcinoma today? A systematic review.

Buti S, Bersanelli M, Sikokis A, Maines F, Facchinetti F, Bria E, Ardizzoni A, Tortora G, Massari F. Buti S, et al. Anticancer Drugs. 2013 Jul;24(6):535-54. doi: 10.1097/CAD.0b013e3283609ec1. Anticancer Drugs. 2013. PMID: 23552469 Review.

6

Axitinib dose titration: what's the limiting factor?

Buti S, Porta C. Buti S, et al. Lancet Oncol. 2013 Nov;14(12):1152-4. doi: 10.1016/S1470-2045(13)70489-3. Epub 2013 Oct 18. Lancet Oncol. 2013. PMID: 24140182 No abstract available.

7

BOLERO-3 results: pharmacological activity or pharmacokinetic effect?

Buti S, Bersanelli M, Tiseo M, Ardizzoni A, Musolino A. Buti S, et al. Lancet Oncol. 2014 Jul;15(8):e304. doi: 10.1016/S1470-2045(14)70242-6. Lancet Oncol. 2014. PMID: 24988929 No abstract available.

8

Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy.

Bersanelli M, Buti S, Camisa R, Brighenti M, Lazzarelli S, Mazza G, Passalacqua R. Bersanelli M, et al. Among authors: buti s. Cancers (Basel). 2014 Sep 30;6(4):2035-48. doi: 10.3390/cancers6042035. Cancers (Basel). 2014. PMID: 25271833 Free PMC article.

9

Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy.

Santoni M, Buti S, Conti A, Porta C, Procopio G, Sternberg CN, Bracarda S, Basso U, De Giorgi U, Rizzo M, Derosa L, Ortega C, Massari F, Milella M, Bersanelli M, Cerbone L, Muzzonigro G, Burattini L, Montironi R, Santini D, Cascinu S. Santoni M, et al. Among authors: buti s. Target Oncol. 2015 Dec;10(4):517-22. doi: 10.1007/s11523-014-0356-3. Epub 2015 Jan 6. Target Oncol. 2015. PMID: 25559290

10

Retroperitoneal cystoadenocarcinoma: a case report with a literature review.

Zanoni D, Sikokis A, Bersanelli M, Gnetti L, Buti S. Zanoni D, et al. Among authors: buti s. Acta Biomed. 2015 Apr 27;86(1):97-105. Acta Biomed. 2015. PMID: 25948035 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

331 results

Search Page

Filters